The subpoena was disclosed by Sanofi in its filing with the Securities and Exchange Commission. All three drugmakers are complying with the probe, according to the report.
The subpoenas come as scrutiny grows over the price of the lifesaving diabetes drug. In recent months the Senate Finance Committee has launched an investigation into the price of insulin; Minnesota and Kentucky filed lawsuits accusing the drugmakers of artificially raising drug prices, and Colorado passed a law capping the price of insulin at $100 per month.
More articles on pharmacy:
Pfizer to merge off-patent business with Mylan
Senate panel advances drug-pricing legislation
Clinics leaving family planning program may have to toss thousands of dollars worth of drugs
